Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age

Br J Clin Pharmacol. 2019 Feb;85(2):316-346. doi: 10.1111/bcp.13756. Epub 2018 Nov 26.

Abstract

Aims: Beta-lactam dose optimization in critical care is a current priority. We aimed to review the pharmacokinetics (PK) of three commonly used beta-lactams (amoxicillin ± clavulanate, piperacillin-tazobactam and meropenem) to compare PK parameters reported in critically and noncritically ill neonates, children and adults, and to investigate whether allometric and maturation scaling principles could be applied to describe changes in PK parameters through life.

Methods: A systematic review of PK studies of the three drugs was undertaken using MEDLINE and EMBASE. PK parameters and summary statistics were extracted and scaled using allometric principles to 70 kg individual for comparison. Pooled data were used to model clearance maturation and decline using a sigmoidal (Hill) function.

Results: A total of 130 papers were identified. Age ranged from 29 weeks to 82 years and weight from 0.9-200 kg. PK parameters from critically ill populations were reported with wider confidence intervals than those in healthy volunteers, indicating greater PK variability in critical illness. The standard allometric size and sigmoidal maturation model adequately described increasing clearance in neonates, and a sigmoidal model was also used to describe decline in older age. Adult weight-adjusted clearance was achieved at approximately 2 years postmenstrual age. Changes in volume of distribution were well described by the standard allometric model, although amoxicillin data suggested a relatively higher volume of distribution in neonates.

Conclusions: Critical illness is associated with greater PK variability than in healthy volunteers. The maturation models presented will be useful for optimizing beta-lactam dosing, although a prospective, age-inclusive study is warranted for external validation.

Keywords: antibiotics; critical care; paediatrics; pharmacokinetics; pharmacometrics.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Adult
  • Age Factors
  • Amoxicillin-Potassium Clavulanate Combination / administration & dosage
  • Amoxicillin-Potassium Clavulanate Combination / pharmacokinetics
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics*
  • Bacterial Infections / drug therapy*
  • Biological Variation, Population
  • Child
  • Critical Illness / therapy*
  • Dose-Response Relationship, Drug
  • Healthy Volunteers
  • Humans
  • Infant, Newborn
  • Meropenem / administration & dosage
  • Meropenem / pharmacokinetics
  • Microbial Sensitivity Tests
  • Piperacillin, Tazobactam Drug Combination / administration & dosage
  • Piperacillin, Tazobactam Drug Combination / pharmacokinetics
  • beta-Lactamase Inhibitors / administration & dosage
  • beta-Lactamase Inhibitors / pharmacokinetics*

Substances

  • Anti-Bacterial Agents
  • beta-Lactamase Inhibitors
  • Piperacillin, Tazobactam Drug Combination
  • Amoxicillin-Potassium Clavulanate Combination
  • Meropenem